The deployment of an innovative medical device such as Thermodiag involves a key step: the implementation of pilot projects under normal conditions of use. These projects, conducted in collaboration with hospital teams, enable the medical and organisational benefits of the device to be assessed in practice.

Thermodiag, a non-invasive medical device for continuous core body temperature monitoring, is intended for patients at high risk of infection, particularly in oncology, resuscitation, intensive care, geriatrics and infectious diseases. In these contexts, fever is often a decisive early warning sign, sometimes even before other clinical signs appear.

The pilot projects enable medical teams to:

• compare continuous monitoring with occasional temperature checks,
• objectively detect early temperature variations,
• measure the impact on clinical responsiveness, caregiver workload and patient safety,
• test the integration of the device into existing protocols and organisations.

For F2D Medical, these deployments in France and internationally also constitute a strategic lever. They enable Thermodiag to be adapted to real-world conditions, user feedback (doctors, nurses, biomedical engineers) to be collected, and clinical benefits in different healthcare systems to be documented.

The pilot programmes are therefore part of a co-construction approach with healthcare professionals, which is essential to support the adoption of an innovative medical device and prepare for its wider deployment.